The EEF1A2 Knockout SK-HEP-1 Polyclonal Cells consist of a CRISPR/Cas9-edited polyclonal population derived from the SK-HEP-1 human liver adenocarcinoma line, featuring targeted disruption of the EEF1A2 gene. This loss-of-function model enables investigation of EEF1A2??s roles in translation elongation and associated cellular processes. As a mixed population of edited cells, it reflects heterogeneous mutation profiles typical of polyclonal knockout pools, providing a robust tool for functional genomics studies without the clonal selection artifacts that may arise in isolated cell lines.
The SK-HEP-1 parental line was established from ascitic fluid of a patient with liver adenocarcinoma and exhibits epithelial morphology with tumorigenic properties. Widely utilized as an in vitro model for hepatocellular carcinoma, SK-HEP-1 cells recapitulate key aspects of liver cancer biology, including dysregulated signaling networks and aberrant protein synthesis. Their use in this knockout product provides a physiologically relevant platform to probe translational control mechanisms in malignancy.
EEF1A2 encodes a tissue-specific isoform of the eukaryotic elongation factor 1A (eEF1A) that delivers aminoacyl-tRNAs to the ribosomal A-site in a GTP-dependent manner, catalyzing peptide bond formation during translation elongation. The EEF1A2 protein is regulated by upstream factors including MYC, YY1, SP1, and the mTORC1 complex, and functions within the broader mTOR signaling axis alongside RPS6KB1, EIF4E, and EEF2. It interacts directly with elongation factor subunits EEF1B2, EEF1D, and EEF1G, as well as aminoacyl-tRNA, GTP, and ribosomal components. Downstream, EEF1A2 activity influences the synthesis of ribosomal proteins, nascent polypeptides, cytoskeletal elements, and proliferation regulators, positioning it as a critical node connecting growth signals to protein homeostasis. Its knockout disrupts this cascade, impairing translation elongation and potentially attenuating oncogenic outputs in cancer cells.
In the context of SK-HEP-1 hepatocellular carcinoma cells, EEF1A2 knockout is expected to perturb the elevated protein synthesis rates often observed in liver cancer, thereby affecting cell proliferation, survival, and invasive capacity. Given EEF1A2??s reported dysregulation in breast, ovarian, and hepatocellular carcinomas, this model facilitates dissection of translation-dependent malignant phenotypes. By eliminating EEF1A2 function, researchers can assess its contribution to cancer cell fitness, evaluate compensatory mechanisms among elongation factors, and explore its role in oncogenic signaling pathways driven by MYC and mTOR.
This polyclonal knockout product is suited for a range of advanced applications, including cancer biology studies to investigate tumor proliferation and metastasis, translation regulation research, and drug target validation. Standard assay platforms such as Western blotting and RT-qPCR confirm gene disruption and downstream effects, while polysome profiling and puromycin incorporation assays measure global protein synthesis rates. Flow cytometry enables cell cycle analysis, and migration/invasion assays assess metastatic potential. RNA-seq provides transcriptome-wide insights into compensatory transcriptional responses. Additionally, drug sensitivity screens can identify therapeutic vulnerabilities arising from EEF1A2 loss. For further details or custom inquiries, please contact Ascent Research.
